Peter C Taylor, EADV 2020 – Seronegative Spondyloarthropathies and the IL23/IL17 Axis

Following his related presentation at the EADV 2020 Virtual Congress, our Editor-in-Chief, Peter C Taylor (University of Oxford, Oxford, UK), took the time to speak with us more about the IL-23 pathway in seronegative spondyloarthropathies.

Questions

1. What are the seronegative spondyloarthropathies? (0:06)
2. What have we learnt in recent years, based on therapeutic advances in this area? (1:16)
3. What does this tell us with respect to the pathobiology related to this range of targeted therapies? (2:53)
4. IL-23 is the common link across the group of disorders. Knowing that the primary pathology in spondyloarthropathies seems to be tendon/bone specific, how can this relationship be explained? Are there any new insights? (3:50)

Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of the EADV 2020 Virtual Congress.